Main Article Content


G.K. Abitayeva

Nazarbayev University, School of Medicine Kerey, Zhanibek Handar st. 5/1, Nur-Sultan, 020000, Kazakhstan
Republican collection of microorganisms, 13/1, Sh. Ualikhanov str., Nur-Sultan, 010000, Kazakhstan

D. Bulanin

Nazarbayev University, School of Medicine Kerey, Zhanibek Handar st. 5/1, Nur-Sultan, 020000, Kazakhstan

E.V. Marchenko

Nazarbayev University, School of Medicine Kerey, Zhanibek Handar st. 5/1, Nur-Sultan, 020000, Kazakhstan

L. Vangelista

Nazarbayev University, School of Medicine Kerey, Zhanibek Handar st. 5/1, Nur-Sultan, 020000, Kazakhstan


Two-component leukotoxins are important virulence factors for Staphylococcus aureus. Despite efforts made to study S. aureus leukotoxins, the direct mechanism of action of these toxins during infection has not been determined. However, the observation that deletion of LukED significantly attenuates highly virulent S. aureus strains supports the hypothesis that selective inhibition of LukE / D may be useful in the development of new aspects of S. aureus infection control. For this purpose, this work was carried out to test the expression and obtain a recombinant form of the LukE protein in E.coli cells. The LukE gene was cloned into the pET28-c (+) / GFP vector containing the gfp gene. Two fused genes carrying a hexahistidine tag were expressed in cells of the E. coli BL21(DE3) strain. It was found that the 6His-GFP-LucE protein aggregates in inclusion bodies. 6His-GFP-LucE was washed out of inclusion bodies with high molar urea. The 6His-GFP-LucE protein was purified by metal affinity chromatography. Research results can be applied to obtain recombinant protein including strategies for inhibition of toxin activity.


LukE, GFP, expression, recombinant protein, E. coli

Article Details


CDC. Antibiotic Resistance Threats in the United States. – Atlanta, GA: U.S. Department of Health and Human Services, CDC. - 2019. at Crossref.

World Health Organization. Antimicrobial resistance: global report on surveillance. World Health Organization. - 2014. URL

Bassetti M., Poulakou G., Ruppe E. Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach. Intensive Care Med., 2017, vol. 43, no. 10, pp.1464-1475. http://doi: 10.1007/s00134--4878-x.

Sommer M.O.A, Munck C., Toft-Kehler R.V., Andersson DI. Prediction of antibiotic resistance: time for a new preclinical paradigm? Nat Rev Microbiol., 2017, vol.15, no.11, pp.689-696. https:// doi: 10.1038/nrmicro.2017.75.

Das S., Dasgupta A., Chopra S. Drug repurposing: a new front in the war against Staphylococcus aureus. Future Microbiol., 2016, vol. 11, pp.1091-1099.

Alonzo F., Kozhaya L., Rawlings S.A., Reyes-Robles T, DuMont A.L., Myszka D.G., Landau N.R., Unutmaz D., Torres V.J. CCR5 is a receptor for Staphylococcus aureus leukotoxin ED. Nature, 2013, vol. 493, pp.51-55.

Reyes-Robles T., Alonzo F 3rd, Kozhaya L., Lacy D.B., Unutmaz D., Torres V.J. Staphylococcus aureus leukotoxin ED targets the chemokine receptors CXCR1 and CXCR2 to kill leukocytes and promote infection. Cell Host Microbe, 2013, vol. 14, pp.453-459.

Nocadello S., Minasov G., Shuvalova L., Dubrovska I., Sabini E., Bagnoli F., Grandi G., Anderson WF. Crystal structures of the components of the Staphylococcus aureus leukotoxin ED. ActaCrystallogr D Struct Biol., 2016, vol. 72, pp.113-120.

Tam K., Schultz M., Reyes-Robles T., Vanwalscappel B., Horton J., Alonzo F 3rd, Wu B., Landau N.R., Torres V.J. Staphylococcus aureus Leukocidin LukED and HIV-1 gp120 Target Different Sequence Determinants on CCR5. MBio., 2016, vol.7, no.6, pp. :e02024-16.

Badarau A., Trstenjak N., Nagy E. Structure and Function of the Two-Component Cytotoxins of Staphylococcus aureus - Learnings for Designing Novel Therapeutics. AdvExp Med Biol., 2017, vol. 966, pp.15-35. https://doi: 10.1007/5584_2016_200.

Secchi M., Grampa V., Vangelista L. Rational CCL5 mutagenesis integration in a lactobacilli platform generates HIV-1 blockers of unprecedented activity. Sci. Rep., 2018, vol. 8, no.1, pp.1890.

Vangelista L., Longhi R., Sironi F., Pavone V., Lusso P. Critical role of the N-loop and beta1-strand hydrophobic clusters of RANTES-derived peptides in anti-HIV activity. BiochemBiophys Res Commun., 2006, vol. 351, pp.664-668.

Vangelista L., Secchi M., Lusso P. Rational design of novel HIV-1 entry inhibitors by RANTES engineering. Vaccine., 2008, vol. 26, pp. 3008-15.

Nisius L., Rogowski M., Vangelista L., Grzesiek S. Large-scale expression and purification of the major HIV-1 coreceptor CCR5 and characterization of its interaction with RANTES. Protein Expr Purif., 2008, vol. 61, pp.155-162.

Secchi M., Xu Q., Lusso P., Vangelista L. The superior folding of a RANTES analogue expressed in lactobacilli as compared to mammalian cells reveals a promising system to screen new RANTES mutants. Protein Expr Purif., 2009, vol. 68, pp.34-41.

Vangelista L., Secchi M., Liu X., Bachi A., Jia L., Xu Q., Lusso P. Engineering of Lactobacillus jensenii to secrete RANTES and a CCR5 antagonist analogue as live HIV-1 blockers. Antimicrob Agents Chemother., 2010, vol.54, pp.2994-3001.

Lusso P., Vangelista L., Cimbro R., Secchi M., Sironi F., Longhi R., Faiella M., Maglio O., Pavone V. Molecular engineering of RANTES peptide mimetics with potent anti-HIV-1 activity. FASEB J., 2011, vol. 25, pp.1230-43.

Secchi M., Longhi R., Vassena L., Sironi F., Grzesiek S., Lusso P., Vangelista L. Enhancement of anti-HIV-1 activity by hot spot evolution of RANTES-derived peptides. Chem Biol., 2012, vol. 19, pp.1579-88.

Secchi M., Vassena L., Morin S., Schols D., Vangelista L. Combination of the CCL5-derived peptide R4.0 with different HIV-1 blockers reveals wide target compatibility and synergic cobinding to CCR5. Antimicrob Agents Chemother., 2014, vol. 58, pp.15-23.